Sign in

VYCO on OTC

VYCOR MEDICAL INC

VYCOR MEDICAL INC is an American surgical and medical instruments and apparatus company.1 It is headquartered in Boca Raton, Florida.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with EBR Systems (United States), FEMASYS INC or Electromedical Technologies, Inc, or pick any stock.

  • TickerVYCO on OTC1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersBoca Raton, Florida1
  • Incorporated inDE2
  • Business address951 Broken Sound Parkway, Suite 320, Boca Raton,, Fl 334872
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

83.8%Gross margin3
1.8%Operating margin3
-3.9%Net margin3
17.2%Revenue growth, 20253
-$18.7KFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Vycor Medical Inc brought in 96% of the revenue VYCOR MEDICAL INC broke down this way in fiscal 2025.

  1. Vycor Medical Inc$1.8M396%up 18% from 2024
  2. Nova Vision Inc$67.3K34%down 8% from 2024
Business segments by year
Business segments20242025
Vycor Medical Inc$1.5M$1.8M
Nova Vision Inc$73.6K$67.3K

Regions

United States brought in 100% of the revenue VYCOR MEDICAL INC broke down this way in fiscal 2025.

  1. United States$1.9M3100%up 17% from 2024
  2. Europe$4.9K30%up 33% from 2024
Regions by year
Regions20242025
United States$1.6M$1.9M
Europe$3.7K$4.9K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue16¢$302.3K
  • Research and development1¢$10.0K
  • Selling, general and admin78¢$1.5M
  • Other costs5¢$93.4K

Out of $1.9M in revenue.3 The company lost money this year.

Financial statements

Revenue456783$1.9M in 2025+34% since 2019
0$500.0K$1.0M$1.5M$2.0M2019: $1.4M$1.4M20192020: $1.1M$1.1M2020−18%2021: $1.4M$1.4M2021+22%2022: $1.2M$1.2M2022−12%2023: $1.5M$1.5M2023+19%2024: $1.6M$1.6M2024+9%2025: $1.9M$1.9M2025+17%
Gross profit456783$1.6M in 2025+24% since 2019
0$500.0K$1.0M$1.5M$2.0M2019: $1.3M$1.3M20192020: $1.0M$1.0M2020−20%2021: $1.3M$1.3M2021+25%2022: $1.1M$1.1M2022−14%2023: $1.3M$1.3M2023+22%2024: $1.4M$1.4M2024+8%2025: $1.6M$1.6M2025+10%
Operating income456783$33.9K in 2025
-$800.0K-$600.0K-$400.0K-$200.0K0$200.0K2019: -$601.4K-$601.4K20192020: -$727.4K-$727.4K2020+21%2021: -$436.0K-$436.0K2021−40%2022: -$306.5K-$306.5K2022−30%2023: $40.2K$40.2K20232024: -$9.1K-$9.1K20242025: $33.9K$33.9K2025
Net income456783-$72.4K in 2025−91% since 2019
-$1.0M-$750.0K-$500.0K-$250.0K02019: -$796.2K-$796.2K20192020: -$822.5K-$822.5K2020+3%2021: -$435.7K-$435.7K2021−47%2022: -$404.9K-$404.9K2022−7%2023: -$69.7K-$69.7K2023−83%2024: -$107.2K-$107.2K2024+54%2025: -$72.4K-$72.4K2025−32%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Revenue$1.9M$1.6M
Cost of Goods Sold$302.3K$166.8K
Gross Profit$1.6M$1.4M
Research and development$10.0K$15.3K
Depreciation and amortization$59.5K$59.5K
Selling, general and administrative$1.5M$1.4M
Total Operating Expenses$1.5M$1.4M
Operating income (loss)$33.9K-$9.1K
Other income$6.0K
Loss on foreign currency exchange-$508-$230
Total Other (Expense) Income-$104.1K-$97.8K
Loss Before Provision for Income Taxes-$70.2K-$107.0K
Net Loss from continuing operations-$70.2K-$107.0K
Loss from discontinued operations, net of tax-$2.2K-$249
Net Loss-$72.4K-$107.2K
Preferred stock dividends-$324.4K-$324.4K
Net Loss Available to Common Stockholders-$396.8K-$431.6K
Comprehensive Loss-$72.4K-$107.2K
Income loss per share from continuing operations - basic-$0-$0
Income loss per share from continuing operations - diluted-$0-$0
Loss per share, loss from discontinued operations - basic$0$0
Loss per share, loss from discontinued operations - diluted$0$0
Income loss available to common stockholders - basic-$0.01-$0.01
Income loss available to common stockholders - diluted-$0.01-$0.01
Weighted Average Number of Shares Outstanding - Basic33.4M shares32.9M shares
Weighted Average Number of Shares Outstanding -Diluted33.4M shares32.9M shares

Compare VYCOR MEDICAL INC with another company

Corporate structure

VYCOR MEDICAL INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of VYCOR MEDICAL INC

  • VYCOR MEDICAL INC Boca Raton, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What VYCOR MEDICAL INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.4M3 Dec 31, 2025$1.4M3 Dec 31, 2024+0.3%
Accumulated depreciation$1.3M3 Dec 31, 2025$1.2M3 Dec 31, 2024+5.2%
Property and equipment, net$133.9K3 Dec 31, 2025$192.7K3 Dec 31, 2024−30.5%
Operating-lease assets (leased space)$55.3K3 Dec 31, 2025$103.7K3 Dec 31, 2024−46.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$87.0K3 Dec 31, 2025$105.6K3 Dec 31, 2024−17.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$159.2K3 Dec 31, 2025$146.1K3 Dec 31, 2024+9.0%
Raw materials$56.1K3 Dec 31, 2025$48.0K3 Dec 31, 2024+16.8%
Finished goods$103.1K3 Dec 31, 2025$98.1K3 Dec 31, 2024+5.2%

Properties, in its own words

The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $4,300 per month, plus other charges of approximately $2,700 per month. The current lease commenced on September 1, 2023 with a termination date of December 31, 2026.

Item 2 of the 10-K filed Mar 31, 2026.11

Leadership

Who has led VYCOR MEDICAL INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Peter C. Zachariou2014–2019

Chair

  1. Adrian Liddell2016

President

  1. David Cantor2016
201520202025
Board members and other officers (5)

Timeline

  1. Aug 14, 20268-K Results of operations18
  2. May 15, 20268-K Results of operations19
  3. Mar 31, 20268-K Results of operations20
  4. Nov 14, 20258-K Results of operations21
  5. Aug 8, 20258-K Results of operations22
  6. May 15, 20258-K Results of operations23
  7. Apr 15, 20258-K Results of operations24
  8. Aug 11, 2014New chief executive Peter C. Zachariou becomes CEO12

Calendar

Coming up

  1. Around Nov 13, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Aug 14, 2026Reported quarterly or annual results18
  2. May 15, 2026Reported quarterly or annual results19
  3. Mar 31, 2026Reported quarterly or annual results20
  4. Nov 14, 2025Reported quarterly or annual results21
  5. Aug 8, 2025Reported quarterly or annual results22
  6. May 15, 2025Reported quarterly or annual results23
  7. Apr 15, 2025Reported quarterly or annual results24

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

41 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 7 major events, 5 insider forms, 5 large holders, 4 other. The latest 20:

  1. Aug 14, 20268-K EDGAR
  2. Aug 14, 202610-Q EDGAR
  3. May 15, 20268-K EDGAR
  4. May 15, 202610-Q EDGAR
  5. Mar 31, 20268-K EDGAR
  6. Mar 31, 202610-K EDGAR
  7. Nov 14, 20258-K EDGAR
  8. Nov 14, 202510-Q EDGAR
  9. Aug 8, 20258-K EDGAR
  10. Aug 8, 202510-Q EDGAR
  11. May 15, 20258-K EDGAR
  12. May 15, 202510-Q EDGAR
  13. Apr 15, 20258-K EDGAR
  14. Apr 15, 202510-K EDGAR
  15. Mar 31, 2025NT 10-K EDGAR
  16. Nov 13, 202410-Q EDGAR
  17. Aug 13, 202410-Q EDGAR
  18. May 15, 202410-Q EDGAR
  19. Apr 16, 202410-K EDGAR
  20. Apr 1, 2024NT 10-K EDGAR

The 41 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How VYCOR MEDICAL INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVYCOR MEDICAL INC1
  • CIK0001424768
  • Employer ID (EIN)20-336921811
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company11
  • Incorporated inDelaware11
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address951 Broken Sound Parkway, Suite 320, Boca Raton,, FL 334871
  • Phone562.558.20001
  • Shares outstanding33,372,796 as of Aug 14, 202610
  • Public float$1.7M as of Jun 30, 202511
  • AuditorPrager Metis CPAs, LLC, Hackensack, New Jersey PCAOB ID 27311
  • On EDGAR sinceMar 3, 20081
  • Filings462 in all: 4 (143), 8-K (57), 10-Q (53), SC 13D/A (53), UPLOAD (20), 10-K (18), CORRESP (16), S-1/A (13)1
    All 33 form types

    POS AM (8), 10-Q/A (7), 3 (7), EFFECT (7), NT 10-K (6), 10-K/A (5), 424B3 (5), D (5), AW (4), D/A (4), DEF 14C (4), NT 10-Q (4), PRE 14C (4), S-1 (3), SC 13D (3), 4/A (2), 8-K/A (2), PRER14C (2), 8-A12B (1), 8-A12G (1), DEFR14C (1), REGDEX (1), REGDEX/A (1), RW (1), S-8 (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Latest 8-K (8-K) Aug 14, 2026

Securities registered for trading

ClassSymbolExchange
Common StockVYCO

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).11

Risk factors and legal proceedings

Legal proceedings

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of the date of this Annual Report, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

The opening of Item 3, Legal Proceedings.11

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25